About this episode:
The switch to remote methodologies as a response to COVID-19 has had a profound effect on the 
conduct of psychiatric disorder trials. Supporting these remote trials requires new tools, sophisticated technology and, most important, deep scientific and clinical expertise.
In this podcast, Mark Opler, PhD, MPH, Chief Research Officer at WCG MedAvante-ProPhase, sits down with WCG President of Patient Advocacy Steve Smith to explore how COVID-19 has forced everyone involved in psychiatric trials to reconsider not only the tools and technology they use, but the entire patient encounter.
That places a tremendous responsibility on sponsors, he says. “I think in this new environment … sponsors have the responsibility to ensure that the right technologies are in place to facilitate remote assessment. They need to be thoughtful and careful about which technologies they use and [ensure] all stakeholders, especially patients, are served and supported in that choice.”
Mark Opler, PhD, MPH, is Chief Research Officer at WCG MedAvante-ProPhase. Dr. Opler was the founder of ProPhase and served as its CEO and Chief Scientific Officer, among other roles. He serves as adjunct assistant professor of psychiatry at New York University and assistant professor of clinical neuroscience at Columbia University’s College of Physicians and Surgeons. He is also leading the development of the forthcoming edition of the PANSS Manual.
Schedule a consultation with our experts
There’s no time for doubt or delays. WCG’s clinical endpoint solutions demystify trial efficacy by reducing clinical trial error rate and, subsequently, the risk of inconclusive and unsalvageable studies. Complete the form to schedule complimentary consultation with our experts today. We’ll help assess your need, and discuss how WCG can assist.